Susan Dana Jones

Title: Susan Dana Jones: Innovator in Antibody Research

Introduction

Susan Dana Jones is a prominent inventor based in Boston, MA (US). She has made significant contributions to the field of antibody research, holding a total of 6 patents. Her work focuses on developing innovative solutions for medical challenges, particularly in cancer treatment and toxic exposure.

Latest Patents

Among her latest patents are the "Humanized and affinity-matured anti-CEACAM1 antibodies." This invention provides recombinant antibodies and antigen-binding fragments that are useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). The methods associated with these antibodies aim to reduce T-cell tolerance and offer potential treatments for cancer. Another notable patent is the "Humanized affinity matured anti-FcRn antibodies," which includes recombinant antibodies that bind to FcRn and block its interaction with human serum albumin. These FcRn-binding proteins have applications in treating various disorders, including acute and chronic toxic exposure.

Career Highlights

Throughout her career, Susan has worked with notable organizations such as Syntimmune, Inc. and The Brigham and Women's Hospital, Inc. Her innovative research has positioned her as a leader in her field, contributing to advancements in therapeutic antibodies.

Collaborations

Susan has collaborated with esteemed colleagues, including Richard S. Blumberg and Robert George Edward Holgate. These partnerships have further enhanced her research and development efforts in antibody technology.

Conclusion

Susan Dana Jones is a trailblazer in the field of antibody research, with a focus on developing innovative treatments for cancer and toxic exposure. Her contributions through her patents and collaborations continue to impact the medical community positively.